Vendor Intelligence Report: Cocer Peptides

Executive summary

Across 9 Finnrick lab tests, Cocer Peptides has 5 passes and 4 failures, for an overall pass rate of 56%. The signal is small but already uneven: Retatrutide is the more defensible Cocer product in the tested set, while Tesamorelin is the weak point. Ratings also tighten under stricter grading, so the methodology view matters.

Cocer’s public trust story is less stable than its homepage suggests. The site markets decades of experience and high purity, but the located public anchors point to a recently created, privacy-shielded retail domain, no identified operators, and no public corporate trail tying the current storefront to a long-running manufacturer.

The brand surface is noisy. The report maps multiple Cocer domains, Facebook identities with differing contact details, a secondary domain now showing Coming Soon, and a confirmed impersonation domain carrying mismatched beauty-site content. Cocer’s Janoshik footprint has expanded, but the entries remain vendor-submitted, leaving COA-to-retail-vial custody unresolved.

Operationally, Cocer is not one-dimensional: buyer reports include quick shipping and customs replacements, but also allegations around “Global Express Shipping LTD” fake tracking, crypto/off-platform payments, polarized support, and weak website-security reputation. The practical read is product-by-product caution, not a blanket verdict.

Inside the full report:

• Per-product pass/fail rates, rating trajectories, and methodology-divergence charts for both Finnrick-tested products.
• WHOIS chronology, homepage-claim comparison, and ownership/personnel search results.
• Domain and channel map covering cocerpeptides.com, .net, .cn, .ca, and the confirmed .top impersonation vector.
• Janoshik public-database footprint analysis separating vendor-submitted COAs from retail-vial verification.
• Logistics, payment, and recourse review, including Global Express Shipping LTD reports and off-platform/crypto payment risk.
• X/web promotion sweep with the direct-link X post and coupon/referral-network limitations.

Risk assessment

• Tesamorelin quality-control risk — high: Finnrick tested Cocer Tesamorelin 4 times; 2 passed and 2 failed, with a current 46.4% rating.
• COA-to-retail-batch verification risk — high: Cocer’s expanded Janoshik footprint remains vendor-submitted; Finnrick failures and customer complaints mean posted COAs should not be treated as retail-vial proof.
• Retatrutide quality-variability risk — medium: Retatrutide is Cocer’s stronger tested product, but Finnrick still recorded 5 tests with 3 pass and 2 fail, with a 74.73% rating.
• Brand-fragmentation and authenticity risk — medium: Multiple Cocer domains and social identities, plus the confirmed cocerpeptides.top scam domain, surfaced without an authoritative official-channel or anti-counterfeit list.
• Unsupported history and corporate-continuity claims — medium: Cocer markets “30 years experience,” while the primary domain was created on March 28, 2025 and no predecessor company or public personnel were verified.
• Ownership-transparency risk — medium: WHOIS privacy, Chongqing registrant location, no public operators, and dead-end LinkedIn/corporate-filing searches leave ownership unverified.
• Payment and dispute-recourse risk — medium: Reported USDT/off-platform payment flow, hostile support complaints, and “Global Express Shipping LTD” fake-tracking reports reduce chargeback and complaint leverage.
• Website-security reputation risk — medium: Gridinsoft rated cocerpeptides.com 32/100 as a “Suspicious Website”; buyers should treat sign-in, personal-data, and payment flows cautiously.